Iovance Biotherapeutics/$IOVA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Iovance Biotherapeutics
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
Ticker
$IOVA
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
838
ISIN
US4622601007
Website
IOVA Metrics
BasicAdvanced
$564M
-
-$1.23
1.06
-
Price and volume
Market cap
$564M
Beta
1.06
52-week high
$12.50
52-week low
$1.64
Average daily volume
12M
Financial strength
Current ratio
4.178
Quick ratio
3.51
Long term debt to equity
5.759
Total debt to equity
6.996
Profitability
EBITDA (TTM)
-365.024
Gross margin (TTM)
21.72%
Net profit margin (TTM)
-176.49%
Operating margin (TTM)
-187.50%
Effective tax rate (TTM)
0.86%
Revenue per employee (TTM)
$250,000
Management effectiveness
Return on assets (TTM)
-27.14%
Return on equity (TTM)
-51.85%
Valuation
Price to revenue (TTM)
2.416
Price to book
0.73
Price to tangible book (TTM)
1.17
Price to free cash flow (TTM)
-1.479
Free cash flow yield (TTM)
-67.63%
Free cash flow per share (TTM)
-114.29%
Growth
Revenue change (TTM)
11,070.12%
Earnings per share change (TTM)
-31.83%
3-year earnings per share growth (CAGR)
-18.73%
10-year earnings per share growth (CAGR)
9.11%
What the Analysts think about IOVA
Analyst ratings (Buy, Hold, Sell) for Iovance Biotherapeutics stock.
Bulls say / Bears say
Iovance's advanced melanoma drug, Amtagvi, received FDA approval in 2024, positioning the company to capitalize on a significant market opportunity. (Nature Reviews Drug Discovery)
Analysts project Iovance's revenues to climb by 118% annually over the next three years, indicating strong growth potential. (Simply Wall St)
Goldman Sachs initiated coverage on Iovance with a 'buy' recommendation and a 12-month price target of $12, suggesting confidence in the company's prospects. (The Motley Fool)
Iovance reported Q1 2025 revenue of $49.3 million, significantly below the average analysts' estimate of $82.4 million, leading to a sharp stock decline. (The Motley Fool)
Piper Sandler downgraded Iovance's stock rating from 'Overweight' to 'Neutral' and reduced the price target to $10, citing a slow launch of Amtagvi. (Nasdaq)
The company is burning through cash rapidly, with a net loss of $113 million reported in Q1 2024, raising concerns about financial sustainability. (StocksToTrade)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.
IOVA Financial Performance
Revenues and expenses
IOVA Earnings Performance
Company profitability
IOVA News
AllArticlesVideos
IOVA IMPORTANT DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Iovance Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – IOVA
GlobeNewsWire·1 day ago
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking
MarketBeat·1 day ago
IOVA Investors Have the Opportunity to Lead the Iovance Biotherapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
GlobeNewsWire·2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Iovance Biotherapeutics stock?
Iovance Biotherapeutics (IOVA) has a market cap of $564M as of June 30, 2025.
What is the P/E ratio for Iovance Biotherapeutics stock?
The price to earnings (P/E) ratio for Iovance Biotherapeutics (IOVA) stock is 0 as of June 30, 2025.
Does Iovance Biotherapeutics stock pay dividends?
No, Iovance Biotherapeutics (IOVA) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next Iovance Biotherapeutics dividend payment date?
Iovance Biotherapeutics (IOVA) stock does not pay dividends to its shareholders.
What is the beta indicator for Iovance Biotherapeutics?
Iovance Biotherapeutics (IOVA) has a beta rating of 1.06. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.